Kidney Transplantation in Sensitized Patients /
Saved in:
Imprint: | Singapore : Springer, 2020. |
---|---|
Description: | 1 online resource (128 pages) |
Language: | English |
Subject: | |
Format: | E-Resource Book |
URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/12602766 |
Table of Contents:
- Intro; Contents; 1: Introduction to Kidney Transplantation in sensitized patients; Definition of Sensitization; Donor-Specific Antibody (DSA); Non-HLA Antibody; Histocompatibility Testing and Virtual Crossmatching; Epitope; Prevalence of Sensitization in Kidney Transplantation; Causes of Sensitization; Approach to the Highly Sensitized Candidate; Allocation System; Acceptable Mismatch Program; Desensitization; Kidney Paired Exchange; Conclusion; References; 2: Preoperative Evaluation of Sensitized Patients; HLA Typing; Serologic Typing; Molecular Typing; HLA Antibody Testing
- Complement-Dependent Cytotoxicity CrossmatchTest Principle and Methods; Interpretation; Flow Cytometry Crossmatch; Principle; Methods; Interpretation; Solid Phase Immunoassay; Principle; Methods; Interpretation; Limitations; C1q SAB Assay; Principle; Methods; Interpretation; Limitations; Epitope Analysis; Correlation of Each Methodology; Cases of Sensitized Patients; A Case with Low-Level Anti-Class I and -Class II HLA Antibodies; A Case with High-Level Anti-Class II HLA Antibodies; A Case with CDC(+) and C1q(+) Anti-HLA Antibodies but with Stable Postoperative Course
- A Case with High-Level Anti-Class II HLA Antibodies with Postoperative DSA(−) ABMRReferences; 3: Preoperative Management (Desensitization); Overview of Desensitization Protocol; Plasmapheresis or Immunoadsorption for Desensitization; IVIG for Desensitization; Rituximab for Desensitization; Proteasome Inhibitors for Desensitization; Complement Inhibitors for Desensitization; Anti-IL-6 Receptor Blockers for Desensitization; IgG-Degrading Enzyme of Streptococcus pyogenes (IdeS) for Desensitization; References
- 4: Induction and Maintenance Immunosuppressants in Sensitized Renal Allograft RecipientsIntroduction; Induction Immunosuppressive Regimen; Antithymocyte Globulin; Rituximab; Bortezomib; Alemtuzumab; Maintenance Immunosuppression; Conclusion; References; 5: Postoperative Management; Monitoring and Prevention of Infectious Disease; Cytomegalovirus; BK Virus; Management of Hyperglycemia; Management of Hypertension; Management of Dyslipidemia; References; 6: Complication from Desensitization; Complication from Rituximab; Infection; AMC Case of Hepatitis in Anti-CD20; Rejection; Lung Disease
- Cardiac DiseaseOthers; Acute Thrombocytopenia; Complication from Bortezomib; GI Toxicity; Peripheral Neuropathy; Hematologic Toxicity; Compensatory Humoral Reaction; Others; Complication from IVIg; Thromboses; Hemolysis; Myocardial Infarction; Others; Complication from Eculizumab; Infection; Others; Complication from C1 Esterase Inhibitor (C1 INH); Infection; Others; Complication from IgG Endopeptidase (IdeS); Rebound Antibody Reaction; Immunogenicity of IdeS; Infection; Complication from Anti-IL-6R mAb (Tocilizumab: TCZ); Infection; Others; Complication from Plasmapheresis